While Merck’s product sales and financial performance have been less than impressive of late, the company’s pipeline is providing hope for the future.

Novartis has undergone a series of transactions that now concentrate the company on three leading divisions with innovation power and worldwide scale: pharmaceuticals, eye care and generics.

Although price restrictions and lowered reimbursements initially affected the company’s 2014 performance, Novo Nordisk reached one of its long-time pipeline goals with the resubmission and approval of Tresiba in the United States.

After the restructuring of its operations, one key divestment, the acquisition of Hospira and some encouraging pipeline advances, Pfizer executives believe the company is on track for a return to significant growth in the future.

With new CEO Olivier Brandicourt at the helm, launches of new products in 2014 and 2015, pipeline progression, R&D collaborations and the reorganization of the company into a new structure coming in 2016, Sanofi is setting the stage for the future.

Snubbed by its initial takeover target Mylan, Teva moved on by acquiring Allergan’s generic business instead.

A listing of the top 50 companies ranked by healthcare revenue.

A listing of the top 50 companies ranked by consolidated revenue.

A listing of the top 50 companies ranked by net income.